Navigation Links
American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation
Date:8/31/2008

MONTPELLIER, France, September 1 /PRNewswire/ -- The ERATO study published today in the American Heart Journal demonstrated, for the first time in patients with permanent atrial fibrillation, that dronedarone (Multaq(R)) significantly reduces mean 24 hour ventricular rate, on top of other rate control agents. The mean heart rate reduction was 11.7 beats per minute (p< 0, 0001) with dronedarone compared to placebo, which is clinically relevant and highly statistically significant. This rate-controlling effect of dronedarone was sustained throughout the six-month trial and was additive to the effect of other rate control therapies. Dronedarone also significantly reduced maximal exercise heart rate by 24.5 beats per minute (p<0,0001) without impairing exercise capacity. Dronedarone was well tolerated with no evidence of organ toxicity or proarrhythmia over six months.

"Effective control of ventricular rate in patients with permanent AF is associated with significant improvements in both symptom control and clinical outcomes," explained principal investigator Jean-Marc Davy of Departement de Cardiologie, CHU Montpellier, France.

AF is the most frequent cardiac rhythm disorder and can be classified into three types: paroxysmal (self-limiting), persistent (responsive to cardioversion) or permanent (continuous atrial fibrillation with cardioversion proven or deemed ineffective). In patients with permanent AF (a substantial subset of the AF population), the only available therapeutic option is to control the ventricular response rate to prevent deterioration of the ventricular function and to minimise the symptoms (rate control strategy). Existing rate control agents (beta blockers, calcium channel blockers and cardiac glycosides) do not always achieve targeted heart rate, mainly due to the poor tolerability of high doses. In that regard, adequate rate control was only achieved in 64% of patients in the AFFIRM trial. Therefore additional therapeutic options to achieve appropriate ventricular rate are needed.

"ERATO demonstrates that dronedarone is well tolerated and demonstrates sustained rate-control efficacy in addition to standard agents, in patients who are only eligible for this therapeutic strategy" said Professor Davy. "In the landmark ATHENA trial, dronedarone has significantly reduced CV hospitalisation and death and has been proven to be effective and safe in paroxysmal and persistent AF patients.

ERATO provides the additive piece to complement earlier dronedarone clinical trial result findings and now confirms its efficacy and safety across the entire spectrum of AF patients," he added.

In ERATO, the incidence of adverse events in the dronedarone arm was not statistically different although marginally higher compared to the placebo group. Gastrointestinal disturbances and mild increases in mean serum creatinine levels were observed more frequently in the dronedarone group, in accordance with previous studies. Creatinine increase occurred early after treatment initiation and reached a plateau after seven days. Values returned to baseline within one week after treatment discontinuation with no impact on renal function. No evidence of thyroid or pulmonary fibrosis was observed with dronedarone and no Torsade de Pointes was reported during the six-month follow-up.

ERATO (The Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation), a randomised, double blind, placebo-controlled, parallel group study, was conducted in 174 adult patients with symptomatic, permanent AF of at least six months' duration, recruited from 38 centres in nine European countries.

ERATO is the first dronedarone study conducted in patients with permanent AF.

The pivotal EURIDIS-ADONIS trials in the maintenance of sinus rhythm (published in the NEJM in 2007) have already demonstrated that dronedarone significantly decreased ventricular rate during a first recurrence of atrial fibrillation in paroxysmal and persistent AF patients.

The well- proven rate-controlling effects of dronedarone observed in ERATO as well as the previously demonstrated rhythm-controlling effects seen in the EURIDIS-ADONIS trials are thought to have contributed to the significant reduction of CV hospitalisations or deaths observed in the landmark ATHENA trial.


'/>"/>
SOURCE CHU Montpellier
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. American Lung Association Study Finds No Evidence of Depression or Suicide Linked to Asthma and Allergy Drug Montelukast
2. Journal of the American Dental Association Publishes Key Clinical Data for the Use of OraVerse(TM) a Local Anesthetic Reversal Agent
3. Alzheimers Foundation of America Survey: Americans With Memory Concerns Fall Short of Talking to Doctors
4. Groundbreaking American Journal of Play from Strong National Museum of Play(R) Premiers July 2008
5. Genaera Corporation Presents Data on Mechanism of Inhibition of PTP-1B for Trodusquemine (MSI-1436) at Federation of American Societies for Experimental Biology (FASEB) Meeting
6. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
7. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
8. Headache Specialists Convene in Boston For 50th Annual American Headache Society Meeting
9. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
10. Results From One-Year Study Suggest Advair(R) Provides Important Benefits for African American Patients With Asthma
11. Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... MOUNTAIN VIEW, Calif. , June 23, 2016 ... 9:00 a.m. CST on Thursday, July 7, 2016 , , ... kayla.belcher@frost.com ) , , , , EXPERT PANELISTS:  ... Sciences, Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, ... The global pharmaceutical industry is witnessing ...
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate ... in Latin America . ... ... ... ...
Breaking Medicine Technology:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
Breaking Medicine News(10 mins):